ライフサイエンスコーパス: Guerin

1 Guerin et al. (2014) report the first direct experimenta

2 vation of the M. bovis bacillus Calmette and Guerin (BCG) vaccine strain selected for an M. bovis PK+

3 augmentation of KCs after Bacille-Calemette-Guerin vaccination largely increased hepatic CETP expres

4 The variable efficacy of Bacille Calmette Guerin (BCG) vaccination against tuberculosis has prompt

5 every year even though the bacille Calmette Guerin (BCG) vaccine has been available for more than 75

6 owth of Mycobacterium bovis bacille Calmette Guerin and Mycobacterium tuberculosis was impaired 7.3-

7 Bacille Calmette Guerin-vaccinated children were more likely to be PfHRP-

8 ad not been vaccinated with Bacille-Calmette Guerin (BCG).

9 d with Mycobacterium bovis bacillus Calmette Guerin (BCG) represents a potential strategy for prevent

10 mutant Mycobacterium bovis bacillus Calmette Guerin (BCG) strains to identify genes that decrease maj

11 culosis (TB) infection and bacillus Calmette Guerin (BCG) vaccination.

12 cine against tuberculosis, bacillus Calmette Guerin (BCG), has traditionally been viewed not to induc

13 The Bacillus Calmette - Guerin (BCG) vaccine provides a critical but limited def

14 ical agent in patients with bacille Calmette-Guerin (BCG) -refractory transitional cell carcinoma of

15 igote vaccine cocktail plus bacille Calmette-Guerin (BCG) adjuvant significantly reduced the incidenc

16 bacterial growth, including Bacille Calmette-Guerin (BCG) and Mycobacterium tuberculosis (MTB) Erdman

17 migration of live M. bovis Bacille Calmette-Guerin (BCG) and to observe interactions with each cell

18 rial challenge model, using bacille Calmette-Guerin (BCG) as a surrogate for a Mycobacterium tubercul

19 Use of bacille Calmette-Guerin (BCG) as a surrogate for human Mycobacterium tube

20 Live attenuated Bacille Calmette-Guerin (BCG) bacillus is the only licensed vaccine for t

21 ycobacterium bovis known as bacille Calmette-Guerin (BCG) has been widely used as a vaccine for preve

22 on with Mycobacterium bovis bacille Calmette-Guerin (BCG) has variable efficacy in preventing tubercu

23 lates of TB disease risk in Bacille Calmette-Guerin (BCG) immunized infants from the MVA85A efficacy

24 ific to Mycobacterium bovis bacille Calmette-Guerin (BCG) in the lungs, and the IFN-gamma CD8 T cell

25 ium and Mycobacterium bovis Bacille Calmette-Guerin (BCG) in vitro.

26 during Mycobacterium bovis Bacille Calmette-Guerin (BCG) infection and a clear memory-type response

27 ding to Mycobacterium bovis bacille Calmette-Guerin (BCG) infection and disrupt granuloma formation,

28 diet on Mycobacterium bovis bacille Calmette-Guerin (BCG) infection.

29 e tuberculosis (TB) vaccine bacille Calmette-Guerin (BCG) is a live attenuated organism, but the muta

30 Bacille Calmette-Guerin (BCG) is an attenuated strain of Mycobacterium bo

31 tion at birth with M. bovis bacille Calmette-Guerin (BCG) is widely used.

32 systemic administration of Bacille Calmette-Guerin (BCG) or beta-glucan reprograms HSCs in the bone

33 ally efficacious TB vaccine bacille Calmette-Guerin (BCG) remain poorly defined.

34 dividuals with a history of Bacille Calmette-Guerin (BCG) vaccination after infancy or with repeated

35 tibody responses induced by bacille Calmette-Guerin (BCG) vaccination and active tuberculosis infecti

36 adermal Mycobacterium bovis bacille Calmette-Guerin (BCG) vaccination as a surrogate for M. tuberculo

37 nmental mycobacteria and/or bacille Calmette-Guerin (BCG) vaccination compromise the estimates derive

38 Bacille Calmette-Guerin (BCG) vaccination has been suggested to have nons

39 Here we show that bacille Calmette-Guerin (BCG) vaccination in healthy volunteers led not o

40 Bacille Calmette-Guerin (BCG) vaccination induces a marked increase in th

41 Bacille Calmette-Guerin (BCG) vaccination remains a cornerstone against t

42 the context of experimental bacille Calmette-Guerin (BCG) vaccination, Ag-specific T cell responses t

43 mately 100 million doses of bacille Calmette-Guerin (BCG) vaccine are given each year to protect agai

44 by the Mycobacterium bovis bacille Calmette-Guerin (BCG) vaccine are multifaceted and poorly underst

45 Because Mycobacterium bovis bacille Calmette-Guerin (BCG) vaccine can confer protection against fatal

46 es regarding the use of the Bacille Calmette-Guerin (BCG) vaccine for tuberculosis vary greatly throu

47 therapeutic agents and the bacille Calmette-Guerin (BCG) vaccine have not significantly affected the

48 n mice infected with either bacille Calmette-Guerin (BCG) vaccine or virulent M. tuberculosis (77 and

49 oma vaccine, Canvaxin, plus Bacille Calmette-Guerin (BCG) versus placebo plus BCG.

50 aques previously exposed to bacille Calmette-Guerin (BCG) were reinfected with BCG, were treated eith

51 previously established that bacille Calmette-Guerin (BCG), an attenuated form of Mycobacterium bovis,

52 Bacille Calmette-Guerin (BCG), an attenuated strain of Mycobacterium bovi

53 dard-of-care immunotherapy, bacille Calmette-Guerin (BCG), constitute a challenging patient populatio

54 Certain vaccines, such as Bacille Calmette-Guerin (BCG), have nonspecific effects, which modulate i

55 effects of vaccines such as bacille Calmette-Guerin (BCG), the licensed TB vaccine.

56 tis and Mycobacterium bovis bacille Calmette-Guerin (BCG), which respectively induce high and low aut

57 cy virus (HIV)-infected and bacille Calmette-Guerin (BCG)-immunized adults with CD4 cell counts of >o

58 5A (M.85A), strongly boosts bacille Calmette-Guerin (BCG)-induced Ag 85A specific CD4(+) and CD8(+) T

59 Mycobacterium bovis strain bacille Calmette-Guerin (BCG)-induced granulomas using an immunocompetent

60 T cells when used alone in bacille Calmette-Guerin (BCG)-naive healthy volunteers.

61 odstream infection (BSI) in bacille Calmette-Guerin (BCG)-vaccinated children with human immunodefici

62 ovis-derived vaccine strain bacille Calmette-Guerin (BCG).

63 orm of Mycobacterium bovis, bacille Calmette-Guerin (BCG).

64 nuated tuberculosis vaccine bacille Calmette-Guerin (BCG).

65 ed with Mycobacterium bovis bacille Calmette-Guerin (BCG).

66 the vaccine strain M. bovis bacille Calmette-Guerin (BCG).

67 2.3 weeks (IQR 1.4-4.6) for bacille Calmette-Guerin (BCG); 2.4 weeks (1.2-3.3) for diphtheria, tetanu

68 Intravesical bacille Calmette-Guerin (including a maintenance regimen) should be used

69 lves the use of recombinant bacille Calmette-Guerin (rBCG) overexpressing protective TB antigens.

70 against Mycobacterium bovis bacille Calmette-Guerin and virulent M. tuberculosis.

71 ontrast, the vaccine strain bacille Calmette-Guerin as well as RD-1 and ESAT-6 mutants of H37Rv faile

72 namide restricted growth of bacille Calmette-Guerin but not wild-type Mycobacterium bovis, which both

73 this article that although bacille Calmette-Guerin controlled M. tuberculosis growth for 7 wk of inf

74 ive combination therapy for bacille Calmette-Guerin failures.

75 s a second-line therapy for bacille Calmette-Guerin failures.

76 e addition of interferon to bacille Calmette-Guerin has proven to be an effective combination therapy

77 Bacille Calmette-Guerin is the most effective therapy for carcinoma in si

78 erculosis vaccines to boost bacille Calmette-Guerin or for those who cannot be immunized with bacille

79 sure of Mycobacterium bovis Bacille Calmette-Guerin or Mycobacterium marinum to thiacetazone, a secon

80 tic granulomas triggered by Bacille Calmette-Guerin or Mycobacterium tuberculosis.

81 on with Mycobacterium bovis bacille Calmette-Guerin resulted in approximately 10-fold-higher bacteria

82 e intravesical therapy with bacille Calmette-Guerin should be considered for ongoing maintenance ther

83 sis and Mycobacterium bovis bacille Calmette-Guerin similarly home to established granulomas in mice.

84 illness, isoniazid use, and bacille Calmette-Guerin strain did not substantially affect vaccine effic

85 uberculous mycobacteria and bacille Calmette-Guerin vaccination may account for a proportion of test

86 Bacille Calmette-Guerin vaccination, tuberculosis prevalence in country o

87 ared with standard M. bovis bacille Calmette-Guerin vaccination.

88 city in those receiving the bacille Calmette-Guerin vaccine and poor sensitivity in individuals with

89 Research into the bacille Calmette-Guerin vaccine demonstrated the importance of comparativ

90 The bacille Calmette-Guerin vaccine provides very efficient protection in sta

91 The failure of the bacille Calmette-Guerin vaccine, synergy between AIDS and TB, and the eme

92 icacy of the currently used bacille Calmette-Guerin vaccine.

93 nd responses to tetanus and Bacille Calmette-Guerin vaccines among HEU and HUU vaccinees.

94 Failure to replace Bacille Calmette-Guerin vaccines with efficacious anti-tuberculosis (TB)

95 sis and Mycobacterium bovis bacille Calmette-Guerin, release MVs when growing in both liquid culture

96 ting ones improved to treat bacille Calmette-Guerin-refractory superficial bladder cancer.

97 r 2013 and January 2016, 36 bacille Calmette-Guerin-vaccinated, healthy UK adults were randomised equ

98 01, in a phase IIa trial of bacille Calmette-Guerin-vaccinated, HIV-uninfected, and Mycobacterium tub

99 these 19 patients with live bacille Calmette-Guerin.

100 ho cannot be immunized with bacille Calmette-Guerin.

101 dder cancer who have failed bacille Calmette-Guerin.

102 modified vaccine mixed with bacille Calmette-Guerin.

103 on with Mycobacterium bovis Bacille-Calmette-Guerin (BCG).

104 to M. tuberculosis from the Bacille-Calmette-Guerin vaccine strain, they currently lack the specifici

105 . tuberculosis and M. bovis Bacille-Calmette-Guerin.

106 We generated a recombinant Bacillus Calmette-Guerin ([BCG] BCG-disA-OE) that overexpresses the endoge

107 n with Mycobacterium bovis bacillus Calmette-Guerin (BCG) administered subcutaneously.

108 only licensed TB vaccine, Bacillus Calmette-Guerin (BCG) against pulmonary TB.

109 d upon Mycobacterium bovis bacillus Calmette-Guerin (BCG) all interfere with the action of the tuberc

110 n with Mycobacterium bovis bacillus Calmette-Guerin (BCG) alone or as a BCG prime/Mtb72F-boost regime

111 l injection of heat-killed bacillus Calmette-Guerin (BCG) and subsequent activation using an intrader

112 onkeys were immunized with bacillus Calmette-Guerin (BCG) and then boosted with Mtb72F in AS02A, prot

113 this study, we found that bacillus Calmette-Guerin (BCG) and viable M. tuberculosis as well as M. tu

114 s a carrier and given with Bacillus Calmette-Guerin (BCG) as an adjuvant, elicited HMW-MAA-specific a

115 sed in Mycobacterium bovis bacillus Calmette-Guerin (BCG) but not when all seven phosphorylation site

116 ids of Mycobacterium bovis bacillus Calmette-Guerin (BCG) by coating the lipids onto 90-microm diamet

117 ion of Mycobacterium bovis bacillus Calmette-Guerin (BCG) continues to be a successful immunotherapy

118 e antituberculosis vaccine bacillus Calmette-Guerin (BCG) contributes to protection against heterolog

119 Using Mycobacterium bovis bacillus Calmette-Guerin (BCG) cultures and TB-positive sputum samples, we

120 rast, the vaccine M. bovis bacillus Calmette-Guerin (BCG) does not stimulate MMP-1 secretion from hum

121 unization with recombinant bacillus Calmette-Guerin (BCG) expressing RSV nucleoprotein prevented beha

122 a since avirulent M. bovis bacillus Calmette-Guerin (BCG) fails to trigger significant expression of

123 Although maintenance bacillus Calmette-Guerin (BCG) for at least 1 year has been recommended, s

124 ents who fail intravesical bacillus Calmette-Guerin (BCG) for nonmuscle invasive bladder cancer (NMIB

125 Vaccination with Bacillus Calmette-Guerin (BCG) has been shown to reduce the severity and p

126 vaccine for tuberculosis, Bacillus Calmette-Guerin (BCG) has been suggested as a possible agent to p

127 Bacillus Calmette-Guerin (BCG) has been used for vaccination against tuber

128 Mycobacterium bovis bacillus Calmette-Guerin (BCG) has been used to treat bladder cancer for a

129 ation of patients for whom bacillus Calmette-Guerin (BCG) has failed, the type of failure (BCG unresp

130 Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer is the onl

131 and immunogenicity of live bacillus Calmette-Guerin (BCG) in a lung-oriented controlled human infecti

132 before revaccination with bacillus Calmette-Guerin (BCG) in healthy, tuberculin skin test-positive (

133 wth of Mycobacterium bovis bacillus Calmette-Guerin (BCG) in human macrophages.

134 Mycobacterium bovis strain bacillus Calmette-Guerin (BCG) in mice.

135 is and Mycobacterium bovis bacillus Calmette-Guerin (BCG) induce potent expansions of human memory Vg

136 s of CD4(+) T cells during bacillus Calmette-Guerin (BCG) infection of mice.

137 lowing Mycobacterium bovis bacillus Calmette-Guerin (BCG) infection.

138 Although Bacillus Calmette-Guerin (BCG) intravesical therapy is a standard treatmen

139 Bacillus Calmette-Guerin (BCG) is the only licensed vaccine for tuberculos

140 d with Mycobacterium bovis bacillus Calmette-Guerin (BCG) nor tuberculin skin test (TST) positive (gr

141 Bacillus Calmette-Guerin (BCG) osteitis was more common in Finland than el

142 tuberculosis and M. bovis bacillus Calmette-Guerin (BCG) Pasteur in vivo and in vitro.

143 rol of Mycobacterium bovis bacillus Calmette-Guerin (BCG) pleural infection in a murine model.

144 h live Mycobacterium bovis Bacillus Calmette-Guerin (BCG) produced large amounts of CXCL1 and CXCL2,

145 e antituberculosis vaccine bacillus Calmette-Guerin (BCG) reduces overall infant mortality.

146 n with Mycobacterium bovis bacillus Calmette-Guerin (BCG) remains the only prophylactic vaccine again

147 d that old age, absence of bacillus Calmette-Guerin (BCG) scar, presence of donor-specific antibody,

148 Bacillus Calmette-Guerin (BCG) seems to have beneficial nonspecific effect

149 The bacillus Calmette-Guerin (BCG) strain of Mycobacterium bovis is used in ma

150 refractory to intravesical bacillus Calmette-Guerin (BCG) therapy and refusing a cystectomy were cons

151 using Mycobacterium bovis bacillus Calmette-Guerin (BCG) to prime and modified vaccinia virus Ankara

152 ure of Mycobacterium bovis bacillus Calmette-Guerin (BCG) to protect against disease, new vaccines ag

153 Taiwan, the inoculation of Bacillus Calmette-Guerin (BCG) Tokyo-172 strain vaccine was postponed from

154 ) are either refractory to bacillus Calmette-Guerin (BCG) treatment or may experience disease relapse

155 according to intravesical Bacillus Calmette-Guerin (BCG) treatment status: no BCG, induction BCG (iB

156 Mycobacterium bovis Bacillus Calmette-Guerin (BCG) use in the treatment of bladder cancer was

157 IGRAs was associated with bacillus Calmette-Guerin (BCG) vaccination (odds ratio: 25.1 [95% confiden

158 ed the association between bacillus Calmette-Guerin (BCG) vaccination and childhood asthma in a birth

159 producing IFN-gamma during bacillus Calmette-Guerin (BCG) vaccination and subsequent M. tuberculosis

160 rventions, such as IPT and bacillus Calmette-Guerin (BCG) vaccination for preventing TB disease among

161 Bacillus Calmette-Guerin (BCG) vaccination induces variable protection aga

162 Mycobacterium bovis bacillus Calmette-Guerin (BCG) vaccination is efficacious for newborns or

163 tudies have suggested that Bacillus Calmette-Guerin (BCG) vaccination may reduce the risk of allergic

164 sociation between national bacillus Calmette-Guerin (BCG) vaccination policy and the prevalence and m

165 ate analyses examined age, bacillus Calmette-Guerin (BCG) vaccination status, and sex as predictor va

166 ced by Mycobacterium bovis bacillus Calmette-Guerin (BCG) vaccination to protect against mycobacteria

167 after primary or secondary bacillus Calmette-Guerin (BCG) vaccination were assessed for Ab responses

168 culosis (strain H37Rv) and bacillus Calmette-Guerin (BCG) vaccine inhibit phagosome maturation in mac

169 The Mycobacterium bovis Bacillus Calmette-Guerin (BCG) vaccine is administered parenterally to inf

170 Bacillus Calmette-Guerin (BCG) vaccine is the most widely administered vac

171 Bacillus Calmette-Guerin (BCG) vaccine is widely used for the prevention o

172 The Bacillus Calmette-Guerin (BCG) vaccine provides protection against tubercu

173 inations studied comprised Bacillus Calmette-Guerin (BCG) vaccine, Triple vaccine, Hepatitis B vaccin

174 proved Mycobacterium bovis bacillus Calmette-Guerin (BCG) vaccine-induced protection was lost in the

175 denitis caused by the live Bacillus Calmette-Guerin (BCG) vaccine.

176 phosphoantigen-containing bacillus Calmette-Guerin (BCG) vaccine.

177 effective than the present bacillus Calmette-Guerin (BCG) vaccine.

178 rapy instillation with the bacillus Calmette-Guerin (BCG) vaccine.

179 ad previously received the bacillus Calmette-Guerin (BCG) vaccine; among this vaccinated group, the r

180 Although Bacillus Calmette-Guerin (BCG) vaccines against tuberculosis have been ava

181 ), and Mycobacterium bovis bacillus Calmette-Guerin (BCG) were studied for their ability to be activa

182 specific antigens and live bacillus Calmette-Guerin (BCG) were used as stimuli, with direct compariso

183 strain Mycobacterium bovis bacillus Calmette-Guerin (BCG), and it is hypothesized that these proteins

184 ates, based on recombinant bacillus Calmette-Guerin (BCG), attenuated Mycobacterium tuberculosis, or

185 model of vaccination with bacillus Calmette-Guerin (BCG), followed by challenge with virulent M. tub

186 he only vaccine available, Bacillus Calmette-Guerin (BCG), has been used since its inception in 1921.

187 rent tuberculosis vaccine, bacillus Calmette-Guerin (BCG), impacts early immunity is poorly understoo

188 ccine, Mycobacterium bovis bacillus Calmette-Guerin (BCG), is contraindicated for immunocompromised i

189 ccine, Mycobacterium bovis bacillus Calmette-Guerin (BCG), is largely ineffective, and ways to enhanc

190 ages infected with M bovis Bacillus Calmette-Guerin (BCG), M phlei, M avium 2151-rough, and M tubercu

191 observed during S. aureus, bacillus Calmette-Guerin (BCG), or E. coli infection, as well as in a mode

192 n with Mycobacterium bovis bacillus Calmette-Guerin (BCG), peaking by days 14-21 posttreatment.

193 nation, in particular with Bacillus Calmette-Guerin (BCG), remain the main strategies to control TB.

194 Bacillus Calmette-Guerin (BCG), the antituberculosis vaccine, localizes wi

195 Bacillus Calmette-Guerin (BCG), the only licensed TB vaccine, provides var

196 Mycobacterium bovis bacillus Calmette-Guerin (BCG), the only TB vaccine in common use, is effe

197 Bacillus Calmette-Guerin (BCG), the tuberculosis vaccine, is an attenuated

198 log in Mycobacterium bovis Bacillus Calmette-Guerin (BCG), we show for the first time that acetylatio

199 ity is Mycobacterium bovis bacillus Calmette-Guerin (BCG), which has been used in newborns for many d

200 vel breast cancer vaccine, Bacillus Calmette-Guerin (BCG)-hIL2MUC1, that consists of BCG and expresse

201 culosis susceptibility and bacillus Calmette-Guerin (BCG)-induced immunity are mostly unknown.

202 e that Mycobacterium bovis bacillus Calmette-Guerin (BCG)-mediated TLR2 signaling-induced iNOS/NO exp

203 85A, Ag85B, and TB10.4, in bacillus Calmette-Guerin (BCG)-primed or unprimed rhesus macaques.

204 gainst Mycobacterium bovis bacillus Calmette-Guerin (BCG).

205 ma and Mycobacterium bovis Bacillus Calmette-Guerin (BCG).

206 nuated Mycobacterium bovis bacillus Calmette-Guerin (BCG).

207 n with Mycobacterium bovis bacillus Calmette-Guerin (BCG).

208 s) and Mycobacterium bovis Bacillus Calmette-Guerin (BCG).

209 ses to Mycobacterium bovis bacillus Calmette-Guerin (BCG).

210 e to stimulation with live bacillus Calmette-Guerin (BCG; LOD score, 3.81; P = 1.40 x 10(-5)).

211 killed Mycobacterium bovis bacillus Calmette-Guerin (HK-BCG) i.p. did not release PGE(2).

212 ts the use of intravesical Bacillus Calmette-Guerin (including a maintenance regimen) for those at hi

213 rt the use of intravesical bacillus Calmette-Guerin (including a maintenance regimen) for those at hi

214 e intravesical maintenance Bacillus Calmette-Guerin (mBCG) and radical cystectomy (RC).

215 (with adjustment for prior bacillus Calmette-Guerin [BCG] vaccination).Measurements and Main Results:

216 th the attenuated M. bovis bacillus Calmette-Guerin [BCG]), and Mycobacterium microti; increasingly r

217 cell responses induced by bacillus Calmette-Guerin and a recombinant subunit protein vaccine to hepa

218 Immunomodulators such as Bacillus Calmette-Guerin and interferon are clinically active in transitio

219 eport, Mycobacterium bovis bacillus Calmette-Guerin and M. tuberculosis H37Ra were used as models of

220 reased Mycobacterium bovis bacillus Calmette-Guerin and Mycobacterium tuberculosis H(37)R(v) burden i

221 n with Mycobacterium bovis bacillus Calmette-Guerin and Mycobacterium tuberculosis.

222 with the Moreau strain of bacillus Calmette-Guerin but not after infection with other strains.

223 erium tuberculosis and the bacillus Calmette-Guerin can be tracked directly in the lungs of living mi

224 n with Mycobacterium bovis bacillus Calmette-Guerin compared with control mice after infection with M

225 oss processing of M. bovis bacillus Calmette-Guerin expressing OVA could be circumvented by pretreati

226 oss processing of M. bovis bacillus Calmette-Guerin expressing OVA, bypassing the inhibition of induc

227 ion by Mycobacterium bovis bacillus Calmette-Guerin failed to induce IRF-1 expression and had no effe

228 tuberculosis comparable to bacillus Calmette-Guerin immunization.

229 n with Mycobacterium bovis bacillus Calmette-Guerin in mice.

230 igands or bacteria such as bacillus Calmette-Guerin increases antitumor immune responses and delays t

231 nuated Mycobacterium bovis bacillus Calmette-Guerin induces less PPARgamma and preferentially uses th

232 lowing Mycobacterium bovis bacillus Calmette-Guerin infection and costimulation with IFN-gamma, we ob

233 resented with disseminated Bacillus Calmette-Guerin infection and oligoclonal T cells with no naive m

234 tuberculosis and M. bovis bacillus Calmette-Guerin infection down-regulated the expression of CIITA/

235 ng Th1 immune responses to Bacillus Calmette-Guerin infection in vivo.

236 uced in macrophages during bacillus Calmette-Guerin infection.

237 bacterium tuberculosis and bacillus Calmette-Guerin infections of macaques induced expression of vari

238 nse to Mycobacterium bovis bacillus Calmette-Guerin infections.

239 Bacillus Calmette-Guerin instillation after removal of the tumor is the fi

240 ogenic Mycobacterium bovis bacillus Calmette-Guerin intracellular survival, downregulated antimicrobi

241 y attenuating mechanism of bacillus Calmette-Guerin is the loss of cytolytic activity mediated by sec

242 Evidence suggests that bacillus Calmette-Guerin is the most effective intravesical therapy for th

243 ore effective vaccine than bacillus Calmette-Guerin is urgently needed.

244 also lowered intracellular Bacillus Calmette-Guerin levels in mammary epithelial cancer MCF-7 cells.

245 lternatives to traditional Bacillus Calmette-Guerin needles and syringes for the administration of fI

246 accine Mycobacterium bovis bacillus Calmette-Guerin or the adoptive transfer of mycobacteria-activate

247 viable Mycobacterium bovis bacillus Calmette-Guerin or TLR ligands.

248 binant Mycobacterium bovis bacillus Calmette-Guerin overexpressing the 30-kDa antigen, C3HeB/FeJ mice

249 at M. marinum and M. bovis bacillus Calmette-Guerin produce a type of spore known as an endospore, wh

250 vealed that currently used bacillus Calmette-Guerin strains vary in their ability to affect correlate

251 Bacillus Calmette-Guerin therapy fails in >50% of cases, and second-line r

252 er (NMIBC) recurrent after bacillus Calmette-Guerin therapy is complex and further complicated by hig

253 e with Mycobacterium bovis bacillus Calmette-Guerin to augment host immunity before infection with vi

254 ther dietary approaches, a Bacillus Calmette-Guerin trial in 1976, molecular-targeted agents, and age

255 in AM and its functions in bacillus Calmette-Guerin vaccination and/or in controlled (latent) versus

256 f the efficacy of standard bacillus Calmette-Guerin vaccination as well as novel TB vaccines now in d

257 While bacillus Calmette-Guerin vaccination plays an important role in reducing t

258 f index cases, the age and bacillus Calmette-Guerin vaccination status of contacts, and study design

259 ble to those achieved with bacillus Calmette-Guerin vaccination.

260 ced by Mycobacterium bovis bacillus Calmette-Guerin vaccination.

261 lacebo together with their Bacillus Calmette-Guerin vaccination.

262 rsons who had received the Bacillus Calmette-Guerin vaccine in households with and without a microbio

263 stimulation with live BCG (Bacillus Calmette-Guerin), and a second locus on chromosome region 3q affe

264 ly available vaccine, BCG (Bacillus Calmette-Guerin), is given intradermally and has variable efficac

265 ylori, Mycobacterium bovis bacillus Calmette-Guerin, and Citrobacter rodentium and of tumor growth in

266 niae, Helicobacter pylori, bacillus Calmette-Guerin, and Mycobacterium tuberculosis) in a murine mode

267 protection at the level of bacillus Calmette-Guerin, and the fusion protein exhibited high predicted

268 red the childhood measles, bacillus Calmette-Guerin, diphtheria-pertussis-tetanus, polio, and materna

269 79c in Mycobacterium bovis bacillus Calmette-Guerin, plays an important role in mycobacterial surviva

270 Mycobacterium bovis bacillus Calmette-Guerin, the only vaccine available against tuberculosis

271 rcinoma in situ, nonuse of bacillus Calmette-Guerin, tumor size > 3 cm, and older age; HRs for progre

272 teria Escherichia coli and bacillus Calmette-Guerin, which increased other DC subsets.

273 Vegf-c is up-regulated in Bacillus Calmette-Guerin- and Mycobacterium tuberculosis-induced granuloma

274 tiation of Th17 cells from bacillus Calmette-Guerin-challenged (BCG-challenged) lung CD4+ T cells.

275 M. tuberculosis var. bovis Bacillus Calmette-Guerin-induced p38 MAPK activity caused a marked increas

276 Bacillus Calmette-Guerin-induced production of the proinflammatory cytokin

277 Granulomas of bacillus Calmette-Guerin-infected humanized mice administered with a TNF-n

278 d in livers and lungs from bacillus Calmette-Guerin-infected humanized mice but not in nonhumanized i

279 m M. tuberculosis- but not bacillus Calmette-Guerin-infected humanized mice.

280 from the serum of M. bovis bacillus Calmette-Guerin-infected mice could also stimulate macrophage pro

281 TB) vaccine trial to boost bacillus Calmette-Guerin-mediated anti-TB immunity despite the induction o

282 termine the feasibility in Bacillus Calmette-Guerin-naive patients.

283 M. bovis bacillus Calmette-Guerin-primed sanroque T cells transferred into Rag1(-/-

284 ward developing agents for bacillus Calmette-Guerin-refractory superficial bladder cancer continue, h

285 development of agents for bacillus Calmette-Guerin-refractory superficial bladder cancer.

286 ent cystoprostatectomy for bacillus Calmette-Guerin-refractory, high-grade noninvasive UC.

287 Furthermore, bacillus Calmette-Guerin-vaccinated IFN-gamma-deficient mice exhibited sig

288 ion by CD4(+) T cells from bacillus Calmette-Guerin-vaccinated mice and show that high-quality microa

289 In bacillus Calmette-Guerin-vaccinated subjects and those with latent TB infe

290 8 healthy, HIV-uninfected, bacillus Calmette-Guerin-vaccinated, South African adults.

291 d with Mycobacterium bovis bacillus Calmette-Guerin.

292 strain Mycobacterium bovis bacillus Calmette-Guerin.

293 strain Mycobacterium bovis bacillus Calmette-Guerin.

294 activity against M. bovis bacillus Calmette-Guerin.

295 s, and Mycobacterium bovis bacillus Calmette-Guerin.

296 travesical instillation of Bacillus Calmette-Guerin.

297 vaccine strain of M. bovis Bacillus Calmette-Guerin; and M. kansasii to demonstrate detection times g

298 autologous tumor cells admixed with Calmette-Guerin bacillus.

299 In this issue of Neuron, Guerin et al. provide novel evidence that distinct parie

300 the Chinese oak silkworm, Antheraea pernyi (Guerin-Meneville) (Lepidoptera: Saturniidae), which is c